157431-09-9

Basic information

• Product Name: N,N-Dimethyl-L-Alanine
• Synonyms: N,N-Dimethyl-L-Alanine;N,N-Dimethyl-L-Ala-OH;(S)-2-(DiMethylaMino)propanoic acid;(R)-2-(dimethylamino)propanoic acid;D-Alanine,N,N-dimethyl-
• CAS NO: 157431-09-9
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.14634
• Mol File: 157431-09-9.mol

Chemical Properties

• Melting Point: 184℃
• Boiling Point: 179.9±23.0℃ (760 Torr)
• Flash Point: 62.6±22.6℃
• Appearance: /
• Density: 1.033±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N,N-Dimethyl-L-Alanine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-Dimethyl-L-Alanine(157431-09-9)
• EPA Substance Registry System: N,N-Dimethyl-L-Alanine(157431-09-9)

Safety Data

• Hazardous Substances Data: 157431-09-9(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
N,N-Dimethyl-L-Alanine is used as a research compound for various scientific studies. Its unique properties and characteristics make it a valuable tool in the exploration of amino acid chemistry and related fields. N,N-Dimethyl-L-Alanine's availability and stability contribute to its widespread use in laboratory settings, where it can be employed in a range of experiments and analyses.
Used in Pharmaceutical Development:
In the pharmaceutical industry, N,N-Dimethyl-L-Alanine is used as a building block for the synthesis of various drug molecules. Its chemical structure allows for the creation of novel compounds with potential therapeutic applications. Researchers can manipulate its properties to develop new drugs or improve existing ones, making it an essential component in the drug discovery process.
Used in Chemical Synthesis:
N,N-Dimethyl-L-Alanine is also utilized in the synthesis of other chemical compounds, particularly in the field of organic chemistry. Its reactivity and compatibility with various chemical groups make it a versatile starting material for the production of a wide array of molecules. This versatility is particularly valuable in the development of new materials, catalysts, and other specialty chemicals.
Used in Analytical Chemistry:
In analytical chemistry, N,N-Dimethyl-L-Alanine serves as a reference material or a standard for the calibration of analytical instruments. Its well-defined chemical properties and purity make it an ideal candidate for use in the development and validation of analytical methods, ensuring accurate and reliable results in various applications, such as quality control, environmental monitoring, and clinical diagnostics.

Upstream product

• 50-00-0 formaldehyd 
• 338-69-2 D-Alanine 

Downstream Products

• 133814-25-2 (R)-2-(dimethylamino)propane-1-ol 
• 5967-73-7 (R)-methadone hydrochloride 
• 7576-16-1 (R)-(-)-2,2-diphenyl-4-dimethylaminopentanenitrile 

Relevant articles and documents

SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE

A method for synthesizing levomethadone hydrochloride including producing (R)-2-(dimethylamino)propan-1-ol by reducing N,N-dimethyl-D-alanine using borax, forming (R)-1-chloro-N,N-dimethylpropane-2-amine hydrochloride by chlorinating the (R)-2-(dimethylamino)propan-1-ol, synthesizing levomethadone nitrile hydrochloride by mixing the (R)-1-chloro-N,N-dimethylpropane-2-amine and diphenylacetonitrile with potassium t-butoxide and producing levomethadone hydrochloride by exposing the levomethadone nitrile hydrochloride to a Grignard reagent.

SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND METHODS FOR USE THEREOF

Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are provided comprising administering a composition comprising an effective amount of levomethadone hydrochloride having not more than 10 ppm dextromethadone.

Jubanines F-J, cyclopeptide alkaloids from the roots of Ziziphus jujuba

Five Ib-type cyclopeptide alkaloids, jubanines F-J (1-5), and three known compounds, nummularine B (6), daechuine-S3 (7), and mucronine K (8) were isolated from the roots of Ziziphus jujuba. Their structures were fully characterized by spectroscopic analyses in combination with chemical derivatization. Compounds 1-3, and 6 were evaluated for their antiviral activity against the porcine epidemic diarrhea virus (PEDV). Compounds 2, 3, and 6 showed potent inhibitory effects on PEDV replication.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.